Airfinity
Airfinity is a London-based predictive analytics company specializing in health intelligence, particularly infectious disease forecasting and pharmaceutical market analysis.
Profile
Provides AI-powered forecasting and risk analysis for infectious diseases and pharmaceutical markets.
Airfinity is a London-based predictive analytics company specializing in health intelligence, particularly infectious disease forecasting and pharmaceutical market analysis. Founded in the mid-2010s, the company has gained prominence for its data-driven models tracking vaccine demand, disease outbreaks, and drug commercialization. Its work during the COVID-19 pandemic, including early warnings about China's zero-COVID policy risks and RSV vaccine market projections, established its credibility with governments and pharmaceutical firms.
Airfinity operates two core platforms: Nexa, an AI scenario engine for drug demand forecasting, and OneID, an infectious disease intelligence system used by 9 of the top 10 pharmaceutical companies in the space. The company was named a Bloomberg UK Startup to Watch in 2023 and won the Financial Times' Tech Champions award that same year. Recent focus areas include obesity drug cost-effectiveness analyses and H5N1 avian flu risk modeling. Airfinity's revenue model combines subscription access to its platforms with custom consulting engagements, though specific financials remain undisclosed.
Who buys this
- Pharmaceutical companies (vaccine/drug manufacturers)
- Government health agencies
- Public health organizations
- Investment firms tracking biotech
- Healthcare procurement teams
Strengths and what to watch
Strengths
- Proprietary models cited by major media (70,000+ citations) including Reuters and NYT
- Specialized focus on infectious disease analytics with 160+ pathogens tracked
- Early mover in combining pharma commercialization data with epidemiological modeling
Watch for
- Reliance on non-public data partnerships with pharma clients creates transparency questions
- Niche focus on infectious diseases limits diversification
- Competition from larger health analytics firms like IQVIA expanding predictive capabilities
Key Information
- Founded
- 2015
- Headquarters
- London, UK
Frequently Asked Questions
What does Airfinity specialize in?
Airfinity provides AI-powered forecasting for infectious diseases and pharmaceutical markets. Their platforms track 160+ pathogens, model vaccine demand, and analyze drug commercialization. Used by top pharma companies and governments, they gained recognition for COVID-19 predictions and RSV market projections. Core offerings include Nexa for drug forecasting and OneID for disease intelligence.
How accurate is Airfinity's disease forecasting?
Airfinity's models have 70,000+ media citations from Reuters and NYT for accurate pandemic predictions. They correctly warned about China's zero-COVID risks and projected RSV vaccine demand. Their disease intelligence system tracks 160+ pathogens, though accuracy varies by region and data availability from government and pharma partners.
Which companies use Airfinity's pharmaceutical analytics?
9 of the top 10 pharmaceutical companies use Airfinity's platforms for drug demand forecasting and market analysis. Clients include vaccine manufacturers, healthcare procurement teams, and investment firms. Their OneID system helps track infectious disease risks while Nexa models drug commercialization scenarios for therapeutic areas like obesity and RSV.
What awards has Airfinity won for its health analytics?
In 2023, Airfinity was named a Bloomberg UK Startup to Watch and won the Financial Times' Tech Champions award. Recognition stems from their COVID-19 modeling, RSV vaccine market projections, and innovative AI platforms that combine epidemiological data with pharmaceutical commercialization insights.
How does Airfinity model RSV vaccine demand?
Airfinity projects RSV vaccine markets using demographic data, immunization rates, and pricing scenarios. Their analysis suggests $10.5B annual revenue potential in G7 countries by 2030. Models incorporate elderly population growth, vaccine efficacy data, and adoption curves from similar immunization programs to forecast doses needed and manufacturer revenues.
What are Airfinity's predictions for H5N1 avian flu risks?
Airfinity actively models H5N1 transmission risks, vaccine production timelines, and potential economic impacts. While full predictions are client-restricted, their public analyses examine scenarios for poultry-to-human spread, antiviral stockpile needs, and manufacturing capacity constraints should large-scale human vaccination become necessary.
Sources
- www.airfinity.com — RSV vaccine market projections
- www.airfinity.com — Monkeypox vaccine demand modeling
- www.airfinity.com — China zero-COVID policy risk analysis
- www.airfinity.com — Recent product launches and awards